The FDA issued final guidances on performance status, washout periods, and laboratory values aimed at expanding oncology trial participation.
|Videos|December 5, 2017
Dr. Hammers on the CheckMate-214 Study for RCC
Author(s)Hans Hammers, MD, PhD
Hans Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the CheckMate-214 study for patients with renal cell carcinoma (RCC).
Advertisement
Hans Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the CheckMate-214 study for patients with renal cell carcinoma (RCC).
CheckMate-214 is a large phase III trial that randomized 1000 patients to nivolumab (Opdivo) plus ipilimumab (Yervoy) or sunitinib (Sutent). The primary analysis was focused on the intermediate- and poor-risk patients, explains Hammers.
A median progression-free survival (PFS) was a challenge to achieve, but according to Hammers, the combination will become the new standard of care.
Advertisement
Related to this article
Faculty reviewed data-driven advances in treatment intensification, sequencing, and emerging biomarkers across the prostate cancer and RCC continuums.
Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.
Phase 2 data show adjuvant penpulimab significantly improves disease-free survival vs surveillance in very high-risk clear cell renal cell carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Finalizes 3 Guidance Documents to Broaden Cancer Clinical Trial Eligibility Criteria
2
Docetaxel Remains Unbeaten in Immunotherapy-Refractory NSCLC
3
Ris-Rez Meets Phase 3 Efficacy End Point for R/R Osteosarcoma
4
HR-Positive/HER2-Negative Metastatic Breast Cancer: Treatment Sequencing After Adjuvant Endocrine Therapy and Transitioning Beyond Endocrine-Based Approaches
5